Isabelle Hardy-Leger1,2, Cécile Charles1,3, Marie Lange4,5,6, Florence Joly4,5,6,7, Pauline Roux1, Aurélie Capel7, Jean Petrucci1,8,9, Olivier Rigal10, Johan Le Fel10, Laurence Vanlemmens11, Sibille Everhard12, Anne-Laure Martin12, Ines Vaz Luis13, Charles Coutant14, Paul Cottu15, Christelle Levy16, Florence Lerebours15, Fabrice Andre13, Idlir Licaj4,6,17, Sarah Dauchy1. 1. Département Interdisciplinaire d'Organisation des Parcours Patients, Gustave Roussy, Université Paris-Saclay, Villejuif, France. 2. Service de médecine interne et d'immunologie clinique, Unité des maladies neurovirales, CHU de Bicêtre, Le Kremlin-Bicêtre, France. 3. Laboratoire de Psychopathologie et Processus de Santé (EA 4057), Université Paris Descartes- Sorbonne Paris Cité, Boulogne-Billancourt, France. 4. Département de recherche clinique, Centre François Baclesse, Caen, France. 5. Université de Normandie, UNICAEN, INSERM, ANTICIPE, Caen, France. 6. Cancer & Cognition Platform, Ligue Contre le Cancer, Caen, France. 7. Département d'Oncologie Médicale, CHU de Caen, Caen, France. 8. AP-HP, hôpital Henri-Mondor - Albert Chenevier, Créteil, France. 9. Fondation FondaMental, fondation de coopération scientifique, Créteil, France. 10. Centre Henri Becquerel, Rouen, France. 11. Centre Oscar Lambret, Lille, France. 12. UNICANCER, Paris, France. 13. Gustave Roussy, Université Paris-Saclay, Inserm, Biomarqueurs prédictifs et nouvelles stratégies thérapeutiques en oncologie, Villejuif, France. 14. Centre Georges-François Leclerc, Dijon, France. 15. Institut Curie, Paris-Saint Cloud, Paris, France. 16. Institut Normand du Sein, Centre François Baclesse, Caen, France. 17. Department of Community Medicine, Faculty of Health Sciences, The UiT Arctic University of Norway, Tromsø, Norway.
Abstract
OBJECTIVE: Cognitive complaints are more frequent in women with breast cancer (BC) than in healthy controls and can be present before any treatment. Findings regarding contributive factors remain inconsistent. This study aimed to identify different groups of patients with cognitive complaints at BC diagnosis and to determine whether these different groups were associated with demographic, medical, or psychological characteristics. METHODS: Cognitive complaints were assessed in a subset of 264 women from the French multicenter prospective CANTO cohort, at baseline before any treatment. Clustering analyzes were performed using the six-cognitive dimension Costa's scoring of the FACT-Cog V3. Univariable analyses were used to study how cognitive function (standardized neuropsychological tests, ICCTF), anxiety, depression, fatigue, and quality of life (HADS, FA12, QLQ-C30) were associated with specific cognitive complaints groups. RESULTS: Results included 263 women (54±11 years), newly diagnosed with BC (69% stages I-III). Four distinct groups emerged, ranged from "no complaints" (22.8%), "low complaints" (55.1), "mixed complaints" (14.5%), to "consistent complaints" (7.6%). No significant differences were found in terms of demographic and medical factors between the four groups. However, the groups with higher proportions of patients with complaints were found to have more impairment in executive function, higher scores of anxiety, depressive symptoms, and fatigue, and lower quality of life, than the groups with lower proportions of cognitive complaints. CONCLUSION: Using complete cognitive assessment prior to BC treatment, we identified four distinct cognitive complaints groups with specific characteristics. This work provides valuable clinical basis to further investigations for a better understanding of cognitive complaints and their associates.
OBJECTIVE: Cognitive complaints are more frequent in women with breast cancer (BC) than in healthy controls and can be present before any treatment. Findings regarding contributive factors remain inconsistent. This study aimed to identify different groups of patients with cognitive complaints at BC diagnosis and to determine whether these different groups were associated with demographic, medical, or psychological characteristics. METHODS: Cognitive complaints were assessed in a subset of 264 women from the French multicenter prospective CANTO cohort, at baseline before any treatment. Clustering analyzes were performed using the six-cognitive dimension Costa's scoring of the FACT-Cog V3. Univariable analyses were used to study how cognitive function (standardized neuropsychological tests, ICCTF), anxiety, depression, fatigue, and quality of life (HADS, FA12, QLQ-C30) were associated with specific cognitive complaints groups. RESULTS: Results included 263 women (54±11 years), newly diagnosed with BC (69% stages I-III). Four distinct groups emerged, ranged from "no complaints" (22.8%), "low complaints" (55.1), "mixed complaints" (14.5%), to "consistent complaints" (7.6%). No significant differences were found in terms of demographic and medical factors between the four groups. However, the groups with higher proportions of patients with complaints were found to have more impairment in executive function, higher scores of anxiety, depressive symptoms, and fatigue, and lower quality of life, than the groups with lower proportions of cognitive complaints. CONCLUSION: Using complete cognitive assessment prior to BC treatment, we identified four distinct cognitive complaints groups with specific characteristics. This work provides valuable clinical basis to further investigations for a better understanding of cognitive complaints and their associates.
Authors: Yu-Yin Allemann-Su; Marcus Vetter; Helen Koechlin; Steven M Paul; Bruce A Cooper; Kate Oppegaard; Michelle Melisko; Jon D Levine; Yvette Conley; Christine Miaskowski; Maria C Katapodi Journal: Cancers (Basel) Date: 2022-07-05 Impact factor: 6.575